Guidelines for therapy of autoimmune liver disease

被引：63

作者：

Ishibashi, Hiromi

Komori, Atsumasa

Shimoda, Shinji

Gershwin, M. Eric

机构：

[1] Nagasaki Med Ctr, NHO, Clin Res Ctr, Nagasaki 8568562, Japan

[2] Nagasaki Univ, Grad Sch Biomed Sci, Dept Hepatol, Nagasaki 852, Japan

[3] Kyushu Univ, Grad Sch Med Sci, Fukuoka 812, Japan

[4] Univ Calif Davis, Sch Med, Genome & Biomed Sci Facil, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA

来源：

SEMINARS IN LIVER DISEASE | 2007年 / 27卷 / 02期

关键词：

treatment; guideline; autoimmune hepatitis; primary biliary cirrhosis; primary sclerosing cholangitis; overlapping syndrome;

D O I：

10.1055/s-2007-979472

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroid-sparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopic, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.

引用

页码：214 / 226

页数：13

共 81 条

[1]

Short-term cyclosporine induces a remission of autoimmune hepatitis in children [J].